Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?
Chioma Odimegwu,Samuel Uwaezuoke,Ugo Chikani,Ngozi Mbanefo,Ken Adiele,Charles Nwolisa,Chizoma Eneh,Chibuzo Ndiokwelu,Somkenechi Okpala,Francis Ogbuka,Kenneth Odo,Ijeoma Ohuche,Chinelo Obiora-Izuka
DOI: https://doi.org/10.2147/dmso.s479077
2024-09-22
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Chioma Laura Odimegwu, 1 Samuel Nkachukwu Uwaezuoke, 1 Ugo N Chikani, 1 Ngozi Rita Mbanefo, 1 Ken Daberechi Adiele, 1 Charles Emeka Nwolisa, 2 Chizoma Ihuarula Eneh, 3 Chibuzo Obiora Ndiokwelu, 1 Somkenechi C Okpala, 1 Francis N Ogbuka, 3 Kenneth E Odo, 1 Ijeoma Onyinyechukwu Ohuche, 1 Chinelo Elizabeth Obiora-Izuka 1 1 Department of Pediatrics, the University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla Enugu, Nigeria; 2 Department of Pediatrics, Federal University Teaching Hospital, Owerri, Nigeria; 3 Department of Pediatrics, Enugu State University Teaching Hospital (ESUTH), Enugu, Nigeria Correspondence: Samuel Nkachukwu Uwaezuoke, Department of Pediatrics, UNTH, Ituku-Ozalla Enugu, Nigeria, Tel +234 8033248108, Email Although genetic, environmental, and lifestyle factors largely contribute to type 2 diabetes mellitus (T2DM) risk, the role of epigenetics in its pathogenesis is now well established. The epigenetic mechanisms in T2DM mainly consist of DNA methylation, histone modifications and regulation by noncoding RNAs (ncRNAs). For instance, DNA methylation at CpG islands in the promoter regions of specific genes encoding insulin signaling and glucose metabolism suppresses these genes. Modulating the enzyme mediators of these epigenetic marks aims to restore standard gene expression patterns and improve glycemic control. In targeting these epigenetic marks, using epigenetic drugs such as DNA methyltransferase (DNAMT), histone deacetylase (HDAC) and histone acetyltransferase (HAT) inhibitors has led to variable success in humans and experimental murine models. Specifically, the United States' Food and Drug Administration (US FDA) has approved DNAMT inhibitors like 5-azacytidine and 5-aza-2ʹ-deoxycytidine for use in diabetic retinopathy: a T2DM microvascular complication. These DNAMT inhibitors block the genes for methylation of mitochondrial superoxide dismutase 2 (SOD2) and matrix metallopeptidase 9 (MMP-9): the epigenetic marks in diabetic retinopathy. Traditional pharmacotherapy with metformin also have epigenetic effects in T2DM and positively alter disease outcomes when combined with epigenetic drugs like DNAMT and HDAC inhibitors, raising the prospect of using epigenetic therapy as a valuable adjunct to pharmacotherapy. However, introducing small interfering RNAs (siRNAs) in cells to silence specific target genes remains in the exploratory phase. Future research should focus on regulating gene expression in T2DM using long noncoding RNA (lncRNA) molecules, another type of ncRNA. This review discusses the epigenetics of T2DM and that of its macro- and microvascular complications, and the potential benefits of combining epigenetic therapy with pharmacotherapy for optimal results. Keywords: type 2 diabetes mellitus, epigenetics, DNA methylation, histone modifications, noncoding RNA regulation, therapeutics, epigenetic therapy In adulthood, type 2 diabetes mellitus (T2DM) is the prevalent form of diabetes, whereas type 1 diabetes mellitus (T1DM) occurs predominantly in children. However, the incidence of T2DM has been increasing in the pediatric age group within the past four decades because of the rising trend of childhood obesity. 1 The disease results from reduced insulin sensitivity at the target cells or decreased production by the pancreatic ß-cells. The putative risk factors include genetics, lifestyle factors, and environmental factors. 2 More importantly, a synergy of these factors rather than a single factor contributes to T2DM risk. Lifestyle and environmental factors are modifiable, while genetics and female sex constitute non-modifiable risk factors. 2 Given the relationship between T2DM and body mass index, women are reportedly more obese than men in some sub-Saharan African settings, 3 underscoring the role of the female sex as a risk factor. Another possible risk factor is maternal nutritional status during fetal embryogenesis, which may play a role through DNA methylation. 4 Poor maternal nutritional status is associated with intra-uterine growth retardation (IUGR) and subsequent low birth weight. A study from the United Kingdom, three decades ago, reported that individuals with a birth weight below 2.5 kg had high odds of developing T2DM later in life. 5 Although the genetic mechanisms of T2DM remain unclear, single nucleotide polymorphism (SNP) is a recognized mechanism that increases T2DM risk. Genome-wide association studies (GWAS) have unraveled sixty-five distinct T2DM-associated genes and their positions on the chromosome. 6 Several genes linked to T2DM within the past decade accounted for just 10% of its total genetic component. 7</ -Abstract Truncated-
endocrinology & metabolism